Showing 4291-4300 of 10100 results for "".
- FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-03-for-treatment-of-psoriasis-in-children-ages-6-to-11/2462045/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. “T
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- Reinforcement Learning Model May Boost AI Skin Cancer Diagnosis Accuracyhttps://practicaldermatology.com/news/reinforcement-learning-model-may-boost-ai-skin-cancer-diagnosis-accuracy/2461897/Artificial intelligence (AI) is already being used to diagnose skin cancer, but so far, it can’t keep pace with the complex decision-making of doctors in practice. Now, an international research team is developing a learning method in which greater accuracy in AI results can be a
- People Who Use Skin-Lightening Products May Be in the Dark About Riskshttps://practicaldermatology.com/news/people-who-use-skin-lightening-products-may-be-in-the-dark-about-risks/2461862/Skin-lightening products can be dangerous, but users aren’t always aware of the risks, a new study finds. To conduct the study, researchers sent an anonymous 19-question survey to individuals with skin of color in the U.S. asking about their demographics, colorism attitudes, skin
- Programmable 3D-printed Wound Dressing Could Improve Treatment for Burns and Aid Drug Deliveryhttps://practicaldermatology.com/news/programmable-3d-printed-wound-dressing-could-improve-treatment-for-burns-and-aid-drug-delivery/2461762/A 3D-printed wound dressing that uses advanced polymers may enhance the healing process for burn patients, aid drug delivery in cancer treatment, and help customize skin care regimens. "To treat burn victims, we can customize the shape using a 3D printer, secondly, t
- Memory Killer Cells May Boost Survival in Melanomahttps://practicaldermatology.com/news/memory-killer-cells-may-boost-survival-in-melanoma/2461758/High levels of memory killer cells in cancer tissue may boost survival in people with melanoma, a new study shows. Certain immune T cells called tissue-resident memory cells are formed locally in the skin and other tissue and protect against infections that they have encountered before.
- Eye on OX40 in AD: Rocatinlimab Performs Well in Two Phase 2 Trialshttps://practicaldermatology.com/news/eye-on-ox40-in-ad-rocatinlimab-performs-well-in-two-phase-2-trials/2461617/OX40 is considered a new potential treatment target in atopic dermatitis (AD), and two new studies of the investigational anti-OX40 monoclonal antibody rocatinlimab may add weight to the evidence. Rocatinlimab inhibits and reduces the number of OX40+ pathogenic T cells responsible
- Bristol Myers Squibb Advances Melanoma Drug Candidate Opdivo in US and Europehttps://practicaldermatology.com/news/bristol-myers-squibb-advances-melanoma-drug-candidate-opdivo-in-us-and-europe/2461583/Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application (BLA) for Opdivo (nivolumab) as monotherapy in the adjuvant setting for the treatment of patients with completely resected stage IIB or IIC melanoma. The company also announced t
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t